Integra LifeSciences Holdings Corporation (IART) Stock Price & Analysis
Integra LifeSciences Holdings Corporation (IART) closed at USD 12.33 on Thursday, October 22, 2026, up 4.10% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 11.84; the Oct 22, 2026 session ranged USD 11.66–12.36 on volume of 1,386,708 shares. Market capitalization is $958.55M, with a 52-week range of USD 8.7–20.49 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:14 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IART.md
Key facts (IART)
- Last four reported quarters (through Jun 30, 2026): revenue $1.65B, net income -$7.2M (-0.4% margin), free cash flow $25.8M (SEC filings).
- Analysts: Hold (mean 3.00 on a 1–5 scale) (12 analysts), mean target USD 16.44 (range 13–23).
- Total return with dividends: 1Y -22.4% vs S&P 500 +14.9%; 5Y -82.6% vs S&P 500 +80.3%.
- Next earnings: 2026-10-21, EPS estimate USD 0.64, revenue estimate $422M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (IART)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.54B | $1.56B | $1.54B | $1.61B | $1.64B | $1.65B |
| Gross profit | $945M | $970M | $885M | $882M | $832M | — |
| Operating income | $197M | $239M | $112M | $28.4M | -$493M | $65.6M |
| Net income | $169M | $181M | $67.7M | -$6.9M | -$516M | -$7.2M |
| EPS (diluted) | $1.98 | $2.16 | $0.84 | -$0.09 | -$6.74 | — |
| Free cash flow | $264M | $222M | $73.1M | $25.0M | -$31.1M | $25.8M |
| Gross margin | 61.2% | 62.3% | 57.4% | 54.8% | 50.9% | — |
| Operating margin | 12.8% | 15.3% | 7.2% | 1.8% | -30.2% | 4.0% |
| Net margin | 11.0% | 11.6% | 4.4% | -0.4% | -31.6% | -0.4% |
| Revenue growth | +12.4% | +1.0% | -1.0% | +4.5% | +1.5% | — |
| Cash + short-term investments | $513M | $457M | $309M | $274M | $264M | — |
| Total debt | $844M | $775M | $775M | $760M | $727M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (IART)
P/S 0.6x · EV/Sales 0.8x · P/FCF 37.2x · P/B 0.9x · FCF yield 2.69% · Earnings yield -0.76% · Net debt $433M · EV $1.39B
P/E at fiscal year-ends: Dec 2023 51.6x.
Analysts (IART)
Consensus Hold (mean 3.00 on a 1–5 scale), 12 analysts; mean target USD 16.44 (low 13, high 23).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | Citigroup | Target lowered | Neutral | $15 → $14 |
| 2026-10-22 | BMO Capital | Target lowered | Market Perform | $15 → $14 |
| 2026-10-22 | Wells Fargo | Target lowered | Equal-Weight | $15 → $13 |
| 2026-10-22 | Citizens | Target lowered | Market Outperform | $25 → $22 |
| 2026-10-22 | JP Morgan | Target lowered | Underweight | $17 → $14 |
| 2026-10-14 | Truist Securities | Target lowered | Hold | $19 → $15 |
| 2026-10-05 | Citigroup | Target lowered | Neutral | $19 → $15 |
| 2026-10-05 | BMO Capital | Target lowered | Market Perform | $18 → $15 |
| 2026-07-30 | Wells Fargo | Target raised | Equal-Weight | $15 → $18 |
| 2026-07-28 | UBS | Initiated | Neutral | $19 |
| 2026-07-16 | Truist Securities | Target raised | Hold | $14 → $19 |
| 2026-07-09 | BMO Capital | Initiated | Market Perform | $19 |
Total return (dividends reinvested) (IART)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -22.4% | -82.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -22.4% | -29.4% |
| Volatility (annualized) | 66.1% | 51.6% |
| Max drawdown | -44.8% (Oct 2025→Mar 2026) | -87.6% (Nov 2021→Mar 2026) |
IART revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Specialty Surgery | $309.3M | 73.9% | +1.7% |
| Tissue Reconstruction | $109.5M | 26.1% | -1.9% |
| Total revenue | $418.8M | 100% | — |
IART revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Neurosurgery | $213.3M | 50.9% | +2.0% |
| Wound Reconstruction Solutions | $81.3M | 19.4% | -4.1% |
| Surgical Instruments | $54.8M | 13.1% | +3.3% |
| ENT Solutions | $41.2M | 9.8% | -1.6% |
| Private Label | $28.2M | 6.7% | +4.8% |
| Total revenue | $418.8M | 100% | — |
IART revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $307.1M | 73.3% | +0.3% |
| Asia Pacific | $48.7M | 11.6% | +2.0% |
| Europe | $42.6M | 10.2% | -0.1% |
| Rest of World | $20.4M | 4.9% | +7.5% |
| Total revenue | $418.8M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
IART company outlook (results filed Oct 21, 2026)
- “For the fourth quarter of 2026, the Company expects reported revenues in the range of $413 million to $433 million, representing a reported decline of -5.2% to -0.5% and an organic decline of -5.1% to -0.4%.”
- “The Company expects adjusted earnings per diluted share in the range of $0.61 to $0.71.”
- “For the full year 2026, the Company expects revenues in the range of $1.634 billion to $1.654 billion representing reported growth of -0.1% to 1.2% and organic growth of -0.3% to 0.9%.”
- “The Company expects adjusted earnings per diluted share in the range of $2.30 to $2.40.”
Analysts expect $422.4M for the current quarter, in line with the midpoint of the company's guidance ($423.0M).
Quoted word-for-word from the SEC 8-K results press release.
IART analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $0.64 | $0.87 | -25.7% | $422.4M | 11 |
| Next quarter (ends Mar 2027) | $0.51 | $0.55 | -8.0% | $388.0M | 7 |
| Current fiscal year (ends Dec 2026) | $2.33 | $2.45 | -4.8% | $1.64B | 11 |
| Next fiscal year (ends Dec 2027) | $2.38 | $2.62 | -9.0% | $1.67B | 12 |
IART options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 100.4% | ±29.8% |
| Dec 18, 2026 | 56 | 56.7% | ±16.3% |
| Mar 19, 2027 | 147 | 73.0% | ±37.3% |
| Jun 17, 2027 | 237 | 76.9% | ±48.4% |
30-day implied volatility 56.3% vs 87.9% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:14 UTC)
| Price | USD 12.33 |
|---|---|
| Change | ▲ 4.10% (up) |
| Previous Close | USD 11.84 |
| Open | USD 11.66 |
| Day Range | USD 11.66 – 12.36 |
| 52-Week Range | USD 8.7 – 20.49 |
| Volume | 1,386,708 shares |
| Market Cap | $958.55M |
| Exchange | NMS |
Technical Analysis (IART)
Nexqual's technical model rates IART "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:14 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 34.6 (neutral) |
| vs SMA50 | Below (USD 15.47) |
| MACD | -0.85 (negative) |
Analyst Ratings (IART)
Wall Street analysts rate IART "Hold" based on 12 analysts, with a mean price target of USD 16.44 (range USD 13–23), per Nexqual as of October 23, 2026 at 09:14 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 16.44 |
| High Target | USD 23 |
| Low Target | USD 13 |
| Buy / Hold / Sell | 3 / 7 / 2 |
Earnings (IART)
| Next Earnings Date | 2026-10-21 |
|---|---|
| EPS Estimate | USD 0.64 |
| Revenue Estimate | $422.42M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD 0.59 vs est 0.56 ▲ beat |
| 2026-06-30 | USD 0.56 vs est 0.48 ▲ beat |
| 2026-03-31 | USD 0.54 vs est 0.4 ▲ beat |
| 2025-12-31 | USD 0.83 vs est 0.8 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:14 UTC.
Financials & Fundamentals (IART)
| Total Revenue | $1.66B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +2.30% |
| Gross Margin | +55.35% |
| Operating Margin | +4.60% |
| Profit Margin | +0.79% |
| Debt / Equity | 1.96 |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $25.80M (1.6% of revenue) |
Source: Nexqual, October 23, 2026 at 09:14 UTC.
Financial Health Score (IART)
Nexqual rates Integra LifeSciences Holdings Corporation's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:14 UTC.
| Growth | Mixed — Revenue +1.5% YoY (annual), slow |
|---|---|
| Profitability | Solid — Gross margin 55%, operating 5% (last 12 months) |
| Balance Sheet | Weak — $274M cash and investments vs $707M debt (Jun 2026, SEC) |
| Cash Flow | Mixed — FCF $26M (last 4 quarters to Jun 2026, SEC), slim 1.6% margin |
| Efficiency | Mixed — No data |
Ownership (IART)
| Insider Ownership | +14.39% |
|---|---|
| Institutional Ownership | +98.47% |
| Shares Outstanding | 77.77M |
| Float | 58.73M |
| Short % of Float | +12.88% |
Source: Nexqual, October 23, 2026 at 09:14 UTC.
Leadership (IART)
Integra LifeSciences Holdings Corporation is led by Stuart M. Essig, CEO, President & Chairman, per Nexqual as of October 23, 2026 at 09:14 UTC.
| CEO, President & Chairman | Stuart M. Essig |
|---|---|
| Executive VP & CFO | Lea Daniels Knight |
| Executive Vice President of Tissue Reconstruction and Distributed Technologies | Robert T. Davis |
| Executive VP & President of International Business | Harvinder Pal Singh |
| Corporate VP & Chief Technology Officer | Teshtar Elavia |
Major Backers & Investors (IART)
Notable institutional backers of Integra LifeSciences Holdings Corporation include Rubric Capital Management LP, Invesco, Morgan Stanley, according to Nexqual as of October 23, 2026 at 09:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Rubric Capital Management LP | 9.97% |
| Invesco | 4.82% |
| Morgan Stanley | 4.62% |
| Fuller & Thaler Asset Management Inc. | 4.42% |
| Paradigm Capital Management | 4.42% |
| AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund | 4.36% |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 3.63% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 13.74% |
| Vanguard Group | 8.6% |
| State Street | 3.79% |
Source: Nexqual, October 23, 2026 at 09:14 UTC.
From Integra LifeSciences Holdings Corporation's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We were the first company to receive an FDA claim for regeneration of dermal tissue and are a world leader in regenerative technology.
- ENT Surgical Solutions: The Company's ENT portfolio comprises a broad range of products including the TruDi® Navigation System featuring navigated surgical instrumentation, the RELIEVA SPINPLUS® Balloon Sinuplasty System, the AERA® Eustachian Tube Dilation System, and the MicroFrance ENT instrumentation line.
- The CSS neurosurgical business consists of a broad portfolio of market-leading brands, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions.
- The 15mm x 60mm and 15mm x 80mm Aurora Surgiscope System version received 510(k) clearance from the FDA in 2025.
Legal & Regulatory Risks (Item 1A, quoted)
- We are subject to stringent domestic and foreign medical device regulations and oversight and any adverse action may adversely affect our ability to compete in the marketplace and our financial condition and business operations.
- We are subject to extensive complex regulatory requirements by domestic and foreign government agencies and any failure to comply with our ongoing responsibilities under their applicable laws and regulations could result in a material adverse impact on our business.
- Our medical device products are subject to reporting requirements and recalls, even after receiving regulatory clearance, approval or certification, which could harm our reputation, business and financial results.
- The adoption of healthcare reform in the U.S. and initiatives sponsored by other governments may adversely affect our business, results of operations and/or financial condition.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NVCR | NovoCure Limited | USD 15.1 | ▼ 3.14% |
| BFLY | Butterfly Network, Inc. | USD 6.81 | ▼ 4.08% |
| ESTA | Establishment Labs Holdings Inc | USD 63.52 | ▲ 1.99% |
| ALMR | Alamar Biosciences, Inc. | USD 29.72 | ▼ 5.5% |
| INSP | Inspire Medical Systems, Inc. | USD 72.66 | ▲ 2.24% |
| AXGN | AxoGen, Inc. | USD 36.68 | ▲ 0.55% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:14 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt